Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis

George Rodrigues; Cary Oberije; Suresh Senan; Kayoko Tsujino; Terry Wiersma; Marta Moreno-Jimenez; Tae Hyun Kim; Lawrence B. Marks; Ramesh Rengan; Luigi De Petris; Sara Ramella; Kim DeRuyck; Nuria Rodriguez De Dios; Andrew Warner; Jeffrey D. Bradley; David A. Palma

doi:10.1016/j.ijrobp.2014.09.033

Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis

George Rodrigues^*, Cary Oberije, Suresh Senan, Kayoko Tsujino, Terry Wiersma, Marta Moreno-Jimenez, Tae Hyun Kim, Lawrence B. Marks, Ramesh Rengan, Luigi De Petris, Sara Ramella, Kim DeRuyck, Nuria Rodriguez De Dios, Andrew Warner, Jeffrey D. Bradley, David A. Palma

^*Corresponding author for this work

GROW - Innovative Cancer Diagnostics & Therapy

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The clinical benefits and risks of dose escalation (DE) for stage III non-small-cell lung cancer (NSCLC) remain uncertain despite the results from Radiation Therapy Oncology Group (RTOG) protocol 0617. There is significant heterogeneity of practice, with many clinicians prescribing intermediate dose levels between the 0617 study arms of 60 and 74 Gy. This study investigated whether this strategy is associated with any survival benefits/risks by analyzing a large multi-institutional database.An individual patient database of stage III NSCLC patients treated with radical intent concurrent chemoradiation therapy was created (13 institutions, n=1274 patients). Patients were divided into 2 groups based on tumor Biological Effective Dose at 10 Gy (BED 10): those receiving standard dose (SD; n=552), consisting of 72Gy ? BED 10 ? 76.8 Gy (eg 60-64 Gy/30-32 fractions [fr]), and those receiving intermediate dose (ID; n=497), consisting of 76.8Gy <BED 10 <100.8 Gy (eg >64 Gy/32 fr and

Original language	English
Pages (from-to)	133-139
Journal	International Journal of Radiation Oncology Biology Physics
Volume	91
Issue number	1
DOIs	https://doi.org/10.1016/j.ijrobp.2014.09.033
Publication status	Published - 1 Jan 2015

Access to Document

10.1016/j.ijrobp.2014.09.033

Cite this

Rodrigues, G., Oberije, C., Senan, S., Tsujino, K., Wiersma, T., Moreno-Jimenez, M., Kim, T. H., Marks, L. B., Rengan, R., De Petris, L., Ramella, S., DeRuyck, K., Rodriguez De Dios, N., Warner, A., Bradley, J. D., & Palma, D. A. (2015). Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis. International Journal of Radiation Oncology Biology Physics, 91(1), 133-139. https://doi.org/10.1016/j.ijrobp.2014.09.033

@article{6d202b3bbeaa4eadb5d67dbbdde07089,

title = "Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis",

abstract = "The clinical benefits and risks of dose escalation (DE) for stage III non-small-cell lung cancer (NSCLC) remain uncertain despite the results from Radiation Therapy Oncology Group (RTOG) protocol 0617. There is significant heterogeneity of practice, with many clinicians prescribing intermediate dose levels between the 0617 study arms of 60 and 74 Gy. This study investigated whether this strategy is associated with any survival benefits/risks by analyzing a large multi-institutional database.An individual patient database of stage III NSCLC patients treated with radical intent concurrent chemoradiation therapy was created (13 institutions, n=1274 patients). Patients were divided into 2 groups based on tumor Biological Effective Dose at 10 Gy (BED 10): those receiving standard dose (SD; n=552), consisting of 72Gy ? BED 10 ? 76.8 Gy (eg 60-64 Gy/30-32 fractions [fr]), and those receiving intermediate dose (ID; n=497), consisting of 76.8Gy 64 Gy/32 fr and ",

author = "George Rodrigues and Cary Oberije and Suresh Senan and Kayoko Tsujino and Terry Wiersma and Marta Moreno-Jimenez and Kim, {Tae Hyun} and Marks, {Lawrence B.} and Ramesh Rengan and {De Petris}, Luigi and Sara Ramella and Kim DeRuyck and {Rodriguez De Dios}, Nuria and Andrew Warner and Bradley, {Jeffrey D.} and Palma, {David A.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/j.ijrobp.2014.09.033",

language = "English",

volume = "91",

pages = "133--139",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Science",

number = "1",

}

Rodrigues, G, Oberije, C, Senan, S, Tsujino, K, Wiersma, T, Moreno-Jimenez, M, Kim, TH, Marks, LB, Rengan, R, De Petris, L, Ramella, S, DeRuyck, K, Rodriguez De Dios, N, Warner, A, Bradley, JD & Palma, DA 2015, 'Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis', International Journal of Radiation Oncology Biology Physics, vol. 91, no. 1, pp. 133-139. https://doi.org/10.1016/j.ijrobp.2014.09.033

Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis. / Rodrigues, George; Oberije, Cary; Senan, Suresh et al.
In: International Journal of Radiation Oncology Biology Physics, Vol. 91, No. 1, 01.01.2015, p. 133-139.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis

AU - Rodrigues, George

AU - Oberije, Cary

AU - Senan, Suresh

AU - Tsujino, Kayoko

AU - Wiersma, Terry

AU - Moreno-Jimenez, Marta

AU - Kim, Tae Hyun

AU - Marks, Lawrence B.

AU - Rengan, Ramesh

AU - De Petris, Luigi

AU - Ramella, Sara

AU - DeRuyck, Kim

AU - Rodriguez De Dios, Nuria

AU - Warner, Andrew

AU - Bradley, Jeffrey D.

AU - Palma, David A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The clinical benefits and risks of dose escalation (DE) for stage III non-small-cell lung cancer (NSCLC) remain uncertain despite the results from Radiation Therapy Oncology Group (RTOG) protocol 0617. There is significant heterogeneity of practice, with many clinicians prescribing intermediate dose levels between the 0617 study arms of 60 and 74 Gy. This study investigated whether this strategy is associated with any survival benefits/risks by analyzing a large multi-institutional database.An individual patient database of stage III NSCLC patients treated with radical intent concurrent chemoradiation therapy was created (13 institutions, n=1274 patients). Patients were divided into 2 groups based on tumor Biological Effective Dose at 10 Gy (BED 10): those receiving standard dose (SD; n=552), consisting of 72Gy ? BED 10 ? 76.8 Gy (eg 60-64 Gy/30-32 fractions [fr]), and those receiving intermediate dose (ID; n=497), consisting of 76.8Gy 64 Gy/32 fr and

AB - The clinical benefits and risks of dose escalation (DE) for stage III non-small-cell lung cancer (NSCLC) remain uncertain despite the results from Radiation Therapy Oncology Group (RTOG) protocol 0617. There is significant heterogeneity of practice, with many clinicians prescribing intermediate dose levels between the 0617 study arms of 60 and 74 Gy. This study investigated whether this strategy is associated with any survival benefits/risks by analyzing a large multi-institutional database.An individual patient database of stage III NSCLC patients treated with radical intent concurrent chemoradiation therapy was created (13 institutions, n=1274 patients). Patients were divided into 2 groups based on tumor Biological Effective Dose at 10 Gy (BED 10): those receiving standard dose (SD; n=552), consisting of 72Gy ? BED 10 ? 76.8 Gy (eg 60-64 Gy/30-32 fractions [fr]), and those receiving intermediate dose (ID; n=497), consisting of 76.8Gy 64 Gy/32 fr and

U2 - 10.1016/j.ijrobp.2014.09.033

DO - 10.1016/j.ijrobp.2014.09.033

M3 - Article

C2 - 25835622

SN - 0360-3016

VL - 91

SP - 133

EP - 139

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 1

ER -

Rodrigues G, Oberije C, Senan S, Tsujino K, Wiersma T, Moreno-Jimenez M et al. Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis. International Journal of Radiation Oncology Biology Physics. 2015 Jan 1;91(1):133-139. doi: 10.1016/j.ijrobp.2014.09.033

Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis

Abstract

Access to Document

Fingerprint

Cite this